Lexicon Pharmaceuticals develops drug candidates and sells INPEFA, a heart failure treatment, from The Woodlands, Texas. It last closed at $1.78 on Nov 17, up 1.71% on the day. The average 12-month price target from 3 analysts is $7.13 (+300.7% from the last close), with a high of $10.00 and a low of $3.40. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $169K, the largest $169K.
Each firm's latest rating on LXRX in the past 90 days
Average 12-month target
$7.13
▲ 300.7% upside
Based on 3 analysts who set a price target on LXRX in the past 90 days. The average target is $7.13, with a high of $10.00 and a low of $3.40, compared with the last close of $1.78.
Low $3.40Avg $7.13High $10.00
Blue marker: last close $1.78
Highest target$10.00
Average target$7.13
Lowest target$3.40
Latest rating changes
CitigroupMaintained
Nov 9Buy$3.40
Cantor FitzgeraldInitiated
Sep 28Buy$8
HC Wainwright & Co.Reiterated
Sep 25Buy$10
Date
Firm
Action
Rating
Price target
Nov 9
Citigroup
Maintained
Buy
$3.40
Sep 28
Cantor Fitzgerald
Initiated
Buy
$8
Sep 25
HC Wainwright & Co.
Reiterated
Buy
$10
Loading…
Technical Analysis
LXRX · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend
The stock is 9% above its 20 day and 2% above its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 57). The nearest support is the Pivot at $1.77, and the nearest resistance the Pivot R1 at $1.82.
Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityNormal, 6.0%/day
Key levels
$2.6852 week high+50.6%
$2.04100 day average+14.6%
$1.97Swing high (Nov 10)+10.7%
$1.90200 day average+6.7%
$1.82Pivot R1+2.2%
$1.78Last close
$1.77Pivot−0.6%
$1.77Swing low (Sep 25)−0.6%
$1.7550 day average−1.7%
$1.73Pivot S1−2.8%
$1.6120 day average−9.6%
$1.1052 week low−38.2%
Indicators
RSI (14)
56.76
Middle of its range
Neutral
MACD
0.03
Above its signal line
Bullish
Stochastic
67.2
Middle of its range
Neutral
ADX (14)
31.2
Trending up
Williams %R
-31.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
65.1
Oversold below −100, overbought above 100
Neutral
Rate of change
+21.9%
Change over 10 sessions
Bullish
ATR (14)
$0.11
Typical daily range, 6.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 14.6%/day
Key levels
$2.6852 week high+50.6%
$2.04100 day average+14.6%
$1.97Swing high (Nov 10)+10.7%
$1.90200 day average+6.7%
$1.82Pivot R1+2.2%
$1.78Last close
$1.77Pivot−0.6%
$1.77Swing low (Sep 25)−0.6%
$1.7550 day average−1.7%
$1.73Pivot S1−2.8%
$1.6120 day average−9.6%
$1.1052 week low−38.2%
Indicators
RSI (14)
47.26
Middle of its range
Neutral
MACD
-0.08
Below its signal line
Bearish
Stochastic
36.7
Middle of its range
Neutral
ADX (14)
25.7
Trending down
Williams %R
-63.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
-54.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−11.0%
Change over 10 sessions
Bearish
ATR (14)
$0.26
Typical daily range, 14.6% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for LXRX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LXRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow LXRX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LXRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXRX is in one of them and how their past LXRX trades turned out.
Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. It markets INPEFA, a tablet taken once a day that is approved in the United States to lower the risk of cardiovascular death and heart failure hospitalization in adults with heart failure or related risk factors. Its drug candidates target hypertrophic cardiomyopathy, type 1 diabetes, and neuropathic pain, and it has licensed an obesity candidate to Novo Nordisk. INPEFA reaches patients through wholesalers, retail pharmacies, hospitals, and a mail order pharmacy, serving prescribers and patients.